Most breast cancer patients with more than 10 nodes that are affected by the cancer have a poor prognosis, yet some survive long-term. Physicians now believe that certain genes in the breast cancer tissue, removed at diagnosis, can help them predict which patients will survive.
With this information, doctors can recommend the most appropriate therapy for an individual patient, for example sparing a woman with a poor prognosis the rigors that accompany aggressive chemotherapy, and enabling h
Researchers at the Breast Care Center at Baylor College of Medicine and The Methodist Hospital have developed a new test to predict which breast cancer tumors will respond to chemotherapy, potentially reducing unnecessary treatment for women with breast cancer, according to data presented at the American Society of Clinical Oncology annual meeting in Chicago.
Using novel DNA array technology, the study identified differences in the gene patterns from tumor samples that predict which patients
Research led by scientists at the U of T and Caprion Pharmaceuticals have uncovered the basis for a diagnostic, immunotherapy and vaccine, providing a way to detect and treat the brain-wasting damage of infectious prions like those found in mad cow disease and its human version, Creutzfeldt-Jakob Disease.
Dr. Neil Cashman, a principal investigator at U of Ts Centre for Research in Neurodegenerative Diseases and professor in the Department of Medicine (neurology) and a Caprion founder,
Study results presented at the 39th annual meeting for the American Society of Clinical Oncology (ASCO) by Chandra P. Belani, M.D., professor of medicine, University of Pittsburgh and co-director, Lung Cancer Program, University of Pittsburgh Cancer Institute (UPCI), demonstrate that a new therapeutic radiation strategy for non-small cell lung cancer (NSCLC) – the most common form of the disease – leads to improved survival for lung cancer patients with locally advanced disease.
n the study
As more is learned about how cancer develops, scientists have begun designing new drugs that directly target cancer cells, leaving healthy ones intact. Having fewer side effects, some of these drugs work by blocking growth signaling processes within cancer cells, while others enlist the body’s immune system to recognize and mount an attack against the cancer cell. But regardless of how they work, most of these drugs are designed to treat a specific cancer and cannot be used to treat other tumor type
University of Pittsburgh researchers report results of first U.S. comparison study at the American Transplant Congress
A new organ preservation solution offers comparable results to a solution currently in widespread use but it is more cost-effective and has several logistical advantages that makes it more practical for keeping donated livers viable before being transplanted, conclude University of Pittsburgh Medical Center (UPMC) researchers who performed the first U.S. study to comp